Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 016915-0252	SERIAL NO. Unassigned
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Gerd GEISSLINGER et al.	
		FILING DATE December 7, 2001	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,788,219	Nov. 29, 1988	Sakurai et al.			
	A2	5,057,304	Oct. 15, 1991	Eichelbaum et al.			
	A3	5,817,800	Oct. 6, 1998	Hoos et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A4	0 595 133	May 4, 1994	EPO				
	A5	0 647 450	April 12, 1995	EPO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A6	Desbene et al., "Application of the ADEPT Strategy to the MDR Resistance in Cancer Chemotherapy," Anti-Cancer Drug Design, Vol. 14, No. 2 (April 1999), pp. 93-106.
	A7	Sperker et al., "Drug Targeting by Glucoronide Prodrugs: Regulation of the Bioactivating Enzyme Beta-Glucuronidase in the Hepatoma Cell Line HEPG2," Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 357, No. 4, Suppl., PP. R19, Meeting Info.: 39th Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology, Mainz, Germany, March 17-19, 1998; German Society.
*	A8	Sperker et al., "The Role of Beta-Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1 (1997), pp. 18-31. Duplicate
*	A9	Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy," Cancer Research, Vol. 58, No. 6 (March 15, 1998), pp. 1195-1201 Duplicate

EXAMINER	DATE CONSIDERED
	6-3-03

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 016915-0252	SERIAL NO. 09/980,824
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Gerd GEISSLINGER et al.	
		FILING DATE 12/07/2001	GROUP ART UNIT Unassigned

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A13	Sperker et al., "Inhibition of Escherichia Coli β-Glucuronidase by Verapamil: Effect on Enterohepatic Cycling of Morphine/Morphine-6-Glucuronide in Rats," European Journal of Clinical Pharmacology, p. 55 (1999).
	A14	Mickisch et al., "Dexverapamil to Modulate Vinblastine Resistance in Metastatic Renal Cell Carcinoma," Cancer Research Clinic of Oncology, Vol. 121, pp. R11-R16 (1995).
	A15	Volm, "Multidrug Resistance and its Reversal," Anticancer Research, Vol. 18, pp. 2905-2918 (1998).
	A16	Wainer, "Stereoisomers in Clinical Oncology: Why it is Important to Know What the Right and Left Hands are Doing," Annals of Oncology, Vol. 4, pp. S7-S13 (1993).
	A17	Simpson, "The Calcium Channel Blocker Verapamil and Cancer Chemotherapy," Cell Calcium, Vol. 6, pp. 449-467 (1985).
	A18	Ling, "Multidrug Resistance: Molecular Mechanisms and Clinical Relevance," Cancer Chemotherapy Pharmacology, Vol. 40, pp. S3-S8 (1997).
	A19	Aasmundstad et al., "Different Biotransformation of Morphine in Isolated Liver Cells from Guinea Pig and Rat," Biochemical Pharmacology, Vol. 46, No. 6, pp. 961-968 (1993).
	A20	Shah et al., "The Calcium Channel Antagonist, Verapamil, Potentiates the Inhibitory Action of Morphine on Intestinal and Biliary Motility," Journal of Pharmaceutical Pharmacology, Vol. 39, pp. 1037-1038 (pp. 1987).
	A21	Krevsky et al., "Effect of Verapamil on Human Intestinal Transit," Digestive Diseases and Sciences, Vol. 37, No. 6, pp. 919-924 (1992).
	A22	Schmidt et al., "Opioid Receptor Agonist Potencies of Morphine and Morphine-6-Glucuronide in the Guinea-Pig Ileum," European Journal of Pharmacology, Vol. 255, pp. 245-247 (1994).
	A23	Hartley et al., "Analysis of Morphine and its 3- and 6-Glucuronides by High Performance Liquid Chromatography with Fluorimetric Detection Following Solid Phase Extraction from Neonatal Plasma," Biomedical Chromatography, Vol. 7, pp. 34-37 (1993).
	A24	Lowry et al., "Protein Measurement with the Folin Phenol Reagent," Journal of Biological Chemistry, Vol. 193, pp. 265-275 (1951).
	A25	Sperker et al., "Interindividual Variability in Expression and Activity of Human β-Glucuronidase in Liver and Kidney: Consequences for Drug Metabolism," The Journal of Pharmacology and Experimental Therapeutics, Vol. 281, No. 2, pp. 914-920 (1997).

6-2-03

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 016915-0252	SERIAL NO. 09/980,824
INFORMATION DISCLOSURE CITATION		APPLICANT Gerd GEISSLINGER et al.	
(Use several sheets if necessary)		FILING DATE 12/07/2001	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,447,719	Sept. 5, 1995	Kamataki	424	195.1	
	A2	5,817,800	Oct. 6, 1998	Bosslet et al.	536	53	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A3	0 822 192	Feb. 4, 1998	EPO				Abstract

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A4	Bernacki et al., "Glycosidases in Cancer and Invasion," Cancer and Metastasis Reviews, Vol. 4, pp. 81-101 (1985).
	A5	Nakajima et al., "Heparanases and Tumor Metastasis," Journal of Cellular Biochemistry, Vol. 36, pp. 157-167 (1988).
	A6	Niwa et al., "A New Potent β-Glucuronidase Inhibitor, D-Glucaro-δ-lactam Derived from Nojirimycin," Journal of Biochemistry, Vol. 72, pp. 207-211 (1972).
	A7	Takasuna et al., "Protective Effects of *Kampo* Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrocholoride (CPT-11), in Rats," Japanese Journal of Cancer Recearch, Vol. 86, pp. 978-984 (1995).
	A8	Sperker et al., "The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1, pp. 18-31 (1997).
	A9	Bosslet et al., "Fusion Protein Mediated Prodrug Activation (FMPA) In Vivo," Cell Biophysics, Vols. 24-25 (1994).
	A10	Bosslet et al., "Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis," Cancer Research, Vol. 54, pp. 2151-2159 (1994).
	A11	Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy," Cancer Research, Vol. 58, pp. 1195-1201 (1998).
	A12	Mürdter et al., "Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: β-Glucuronidase Mediates Release of Doxorubicin from a Glucuronide Prodrug (HMR 1826) at the Tumor Site," Cancer Research, Vol. 57, pp. 2440-2445 (1997).

EXAMINER	**DATE CONSIDERED**
	6-2-03

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**